NO951061L - Antibody conjugates with improved properties - Google Patents
Antibody conjugates with improved propertiesInfo
- Publication number
- NO951061L NO951061L NO951061A NO951061A NO951061L NO 951061 L NO951061 L NO 951061L NO 951061 A NO951061 A NO 951061A NO 951061 A NO951061 A NO 951061A NO 951061 L NO951061 L NO 951061L
- Authority
- NO
- Norway
- Prior art keywords
- improved properties
- antibody conjugates
- conjugate
- mammal
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Abstract
Det blir beskrevet et oppløselig konjugat hvor et bæreprotein er kovalent bundet til et monoklonalt antistoff, et farmasøytisk preparat omfattende et slikt konjugat og en fremgangmsåte for fremstillingen derav. Et konjugat Ifølge oppfinnelsen er nyttig f.eks. for aktiv immunoterapi av et pattedyr, spesielt et menneske.A soluble conjugate is described in which a carrier protein is covalently linked to a monoclonal antibody, a pharmaceutical composition comprising such a conjugate and a method of making the same. A conjugate according to the invention is useful e.g. for active immunotherapy of a mammal, especially a human.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810173 | 1994-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO951061D0 NO951061D0 (en) | 1995-03-20 |
NO951061L true NO951061L (en) | 1995-09-22 |
Family
ID=8218230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO951061A NO951061L (en) | 1994-03-21 | 1995-03-20 | Antibody conjugates with improved properties |
Country Status (11)
Country | Link |
---|---|
JP (1) | JPH0820545A (en) |
KR (1) | KR950031111A (en) |
AU (1) | AU1481795A (en) |
CA (1) | CA2144936A1 (en) |
FI (1) | FI951276A (en) |
HU (1) | HUT71776A (en) |
IL (1) | IL113022A (en) |
NO (1) | NO951061L (en) |
NZ (1) | NZ270734A (en) |
RU (1) | RU95104325A (en) |
ZA (1) | ZA952269B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865737B1 (en) * | 2004-02-03 | 2006-03-31 | Anteis Sa | BIOCOMPATIBLE RETICLE GEL |
-
1995
- 1995-02-24 HU HU9500586A patent/HUT71776A/en unknown
- 1995-03-14 AU AU14817/95A patent/AU1481795A/en not_active Abandoned
- 1995-03-17 RU RU95104325/14A patent/RU95104325A/en unknown
- 1995-03-17 FI FI951276A patent/FI951276A/en unknown
- 1995-03-17 CA CA002144936A patent/CA2144936A1/en not_active Abandoned
- 1995-03-17 IL IL11302295A patent/IL113022A/en not_active IP Right Cessation
- 1995-03-17 JP JP7059022A patent/JPH0820545A/en active Pending
- 1995-03-17 NZ NZ270734A patent/NZ270734A/en unknown
- 1995-03-20 KR KR1019950005739A patent/KR950031111A/en not_active Application Discontinuation
- 1995-03-20 ZA ZA952269A patent/ZA952269B/en unknown
- 1995-03-20 NO NO951061A patent/NO951061L/en unknown
Also Published As
Publication number | Publication date |
---|---|
FI951276A0 (en) | 1995-03-17 |
NO951061D0 (en) | 1995-03-20 |
AU1481795A (en) | 1995-09-28 |
JPH0820545A (en) | 1996-01-23 |
KR950031111A (en) | 1995-12-18 |
IL113022A0 (en) | 1995-06-29 |
FI951276A (en) | 1995-09-22 |
ZA952269B (en) | 1995-09-21 |
CA2144936A1 (en) | 1995-09-22 |
HU9500586D0 (en) | 1995-04-28 |
HUT71776A (en) | 1996-01-29 |
IL113022A (en) | 2000-02-29 |
NZ270734A (en) | 1997-05-26 |
RU95104325A (en) | 1996-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1135498E (en) | Antibody variants with higher binding affinity compared to parent antibodies | |
CO4850562A1 (en) | PROCESS TO PRODUCE A CONCENTRATED PREPARATION OF ANTIBODIES | |
MXPA02007756A (en) | Antibodies that bind human interleukin 18 and methods of making and using. | |
ATE383430T1 (en) | RECOMBINANT ANTIBODIES AND IMMUNE CONJUGATES TARGETED AT CD22-BEARING CELLS AND TUMORS | |
PL248202A1 (en) | Process for preparing conjugate with chain b of toxin and method of manufacture of cytotoxic composition | |
NO984136D0 (en) | Humanized chimeric antibody molecule for use as a dianostic, and diagnostic composition comprising such an antibody molecule | |
DE69729283D1 (en) | GLYCOSYLATED IgG ANTIBODIES | |
EP0683234A4 (en) | ANTIBODY AGAINST -g(b)-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF. | |
AU563356B2 (en) | Conjugate of enzyme and antibody | |
DK0969873T3 (en) | Multiple carbohydrate-containing glycopeptide antigens, vaccine containing them, and use thereof | |
AU628948B2 (en) | Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof | |
FI950062A (en) | Foroactivation of proteins for conjugation purposes | |
EP0350690A3 (en) | Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom | |
IS4922A (en) | Polypeptides capable of forming antigen-specific forms of specificity for the resus D antigen, the DNA that represents them, and the method of preparing a saline and its use | |
PT97423A (en) | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES CONJUGATES FOR THE TREATMENT OF NEOPLASMS | |
DE69328779D1 (en) | BENZODIAZEPINE DERIVATIVES AND THEIR CONJUGATES WITH PROTEINS AND POLYPEPTIDES | |
NO951061L (en) | Antibody conjugates with improved properties | |
ES2082132T3 (en) | COMPOSITION CONTAINING AT LEAST TWO DIFFERENT ANTIBODIES OR FRAGMENTS OF THEM. | |
DE69611037D1 (en) | METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE CONJUGATES AND MARKED COMPOUNDS | |
Fodstad et al. | New indirect approach to the therapeutic use of immunotoxins | |
IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same | |
AU3637195A (en) | Broadly reactive opsonic antibodies reactive with common staphylococcal antigens | |
DK0513565T3 (en) | Monoclonal antibodies against the plasmin-antiplasmin complex, method for their preparation and their use | |
DK0889907T3 (en) | Monoclonal antibodies that bind human growth hormone (hGH) | |
JPH0469345A (en) | Method for removing tumorous cell |